Curis (CRIS) Licenses GDC-0917 from Roche's (RHHBY) Genentech
Tweet
Share
E-mailGet Alerts CRIS Hot Sheet
Join SI Premium – FREE
Curis, Inc. (Nasdaq: CRIS) has licensed from Genentech, a member of the Roche Group, (OTCBB: RHHBY), exclusive, worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins.
Curis, Inc. (Nasdaq: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has licensed from Genentech, a member of the Roche Group, (SIX: RO, ROG; OTCQX: RHHBY), exclusive, worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins.
Curis, Inc. (Nasdaq: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has licensed from Genentech, a member of the Roche Group, (SIX: RO, ROG; OTCQX: RHHBY), exclusive, worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves first treatment for Alexander disease
- Brookfield to redeem two Series of preference shares in November
- Baker Hughes wins bp North Sea stimulation services contract
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
